Dexamethasone News and Research

RSS

Patrys reports positive results from PAT-SM6 clinical trial in patients with multiple myeloma

Patrys Limited, a clinical stage biotechnology company, is pleased to announce the clinical results from a patient treated with PAT-SM6 in combination with other marketed multiple myeloma drugs.

28 May 2014

Pemetrexed plus erlotinib shows benefits in NSCLC

Pemetrexed used in combination with erlotinib may have clinical advantage over single-agent pemetrexed when used as a second-line treatment in patients with non-squamous non-small-cell lung cancer, researchers report.

20 May 2014

Elotuzumab granted Breakthrough Therapy Designation for treatment of multiple myeloma

Bristol-Myers Squibb Company and AbbVie today announced that the U.S. Food and Drug Administration (FDA) has granted elotuzumab, an investigational humanized monoclonal antibody, Breakthrough Therapy Designation for use in combination with lenalidomide and dexamethasone for the treatment of multiple myeloma in patients who have received one or more prior therapies.

20 May 2014

Access provides update on new formulation of anti-inflammatory drug amlexanox

ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP) provided an update on a new formulation of the anti-inflammatory drug amlexanox, called LexaGard™, for the treatment of inflammatory and ulcerative conditions of the esophagus.

8 Apr 2014

Heron initiates SUSTOL Phase 3 clinical trial for CINV prevention associated with emetogenic chemotherapy

Heron Therapeutics, Inc., a specialty pharmaceutical company, today announced the initiation of a Phase 3 clinical trial of SUSTOL™ (APF530), the Company's lead product candidate for the prevention of chemotherapy-induced nausea and vomiting (CINV) associated with moderately and highly emetogenic chemotherapy.

31 Mar 2014

Ocular Therapeutix starts Phase 3 clinical program to evaluate safety, efficacy of dexamethasone

Ocular Therapeutix, Inc. announces the start of its Phase 3 clinical program to evaluate the safety and efficacy of their sustained release dexamethasone, an ophthalmic corticosteroid for the treatment of post-operative inflammation and pain following cataract surgery. Ocular Therapeutix's dexamethasone is administered as a one-time, bioabsorbable intracanalicular plug for release of the steroid to the ocular surface for up 30 days.

18 Mar 2014

Pharmacyclics total revenue for fourth quarter 2013 increases 113% to $123.6 million

Pharmacyclics, Inc. today reported financial results and recent developments for the quarter and year ended December 31, 2013.

20 Feb 2014

New treatments for depression on the horizon

New insights into the physiological causes of depression are leading to treatments beyond common antidepressants such as Prozac and Zoloft, researchers are reporting in the in the journal Current Psychiatry.

15 Feb 2014

IMF announces approval of POMALYST medication in Canada for patients with myeloma

The International Myeloma Foundation - improving the quality of life of myeloma patients while working toward prevention and a cure - said POMALYST (pomalidomide) approval by Health Canada provides patients the most up-to-date oral therapy available for patients who have exhausted all other treatments.

11 Feb 2014

No added benefit from aflibercept, shows study

For the third time in one year, the German Institute for Quality and Efficiency in Health Care (IQWiG) dealt with the drug aflibercept. In an early benefit assessment pursuant to the Act on the Reform of the Market for Medicinal Products (AMNOG), the Institute now examined whether aflibercept (trade name: Eylea) offers an added benefit over the appropriate comparator therapy in visual impairment due to macular oedema following occlusion of the central retinal vein.

8 Jan 2014

First patient enrolled in Otonomy's pivotal Phase 2b study of OTO-104 for Meniere's disease

Otonomy, Inc., a clinical stage biopharmaceutical company developing innovative therapeutics for diseases and disorders of the inner and middle ear, today announced enrollment of the first patient in its pivotal Phase 2b study of OTO-104 for the reduction of vertigo in patients with unilateral Meniere's disease.

11 Dec 2013

Celgene subsidiary presents REVLIMID study results on lymphoma at ASH annual meeting

Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation (NASDAQ:CELG) today announced that results from two studies of REVLIMID (lenalidomide) combinations in patients with diffuse large B-cell lymphoma (DLBCL) were presented at the American Society of Hematology annual meeting in New Orleans, La.

11 Dec 2013

Celgene: FIRST trial meets primary endpoint in patients newly diagnosed with multiple myeloma

Celgene today announced that data from the FIRST (Frontline Investigation of lenalidomide and dexamethasone vs. standard thalidomide) trial was presented on Sunday 8 December, during the Plenary Scientific Session at the 55th American Society Hematology annual meeting in New Orleans. FIRST (MM-020/IFM 07-01) a phase III, multi-centre study in patients newly diagnosed with multiple myeloma and ineligible for stem cell transplant, included 72 patients from the UK.

11 Dec 2013

Takeda presents clinical study results of oral proteasome inhibitor MLN9708 in multiple myeloma patients

Takeda Pharmaceutical Company Limited today announced final Phase 1 and preliminary Phase 2 results of a study combining oral investigational MLN9708 administered twice a week with lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma.

10 Dec 2013

Acetylon Pharmaceuticals presents positive interim data from two ricolinostat clinical trials at ASH 2013

Acetylon Pharmaceuticals, Inc., the leader in the development of selective histone deacetylase inhibitors for enhanced therapeutic outcomes, today announced that positive interim clinical data from the two proof-of-concept clinical trials with selective HDAC6 inhibitor, ricolinostat (ACY-1215), were presented at the 55th Annual Meeting of the American Society of Hematology in New Orleans, LA.

9 Dec 2013

NOXXON Pharma reports interim data from two phase IIa studies of anti-CXCL12/SDF-1 Spiegelmer NOX-A12

NOXXON Pharma disclosed interim data from two independent clinical phase IIa studies of the anti-CXCL12/SDF-1 Spiegelmer olaptesed pegol (NOX-A12) at the 55th annual meeting of the American Society of Hematology in New Orleans, LA, USA from 7-10 December 2013.

9 Dec 2013

Novartis to present updates on broad cancer portfolio at ASH and SABCS symposiums

Novartis will present updates on its broad cancer portfolio with more than 240 abstracts at the upcoming American Society of Hematology (ASH) annual meeting and CTRC-AACR San Antonio Breast Cancer Symposium (SABCS).

4 Dec 2013

Scientists to develop on-demand drug-delivery system for pain management in osteoarthritis patients

Scientists are reporting development of a squishy gel that when compressed - like at a painful knee joint - releases anti-inflammatory medicine. The new material could someday deliver medications when and where osteoarthritis patients need it most. Their study appears in the ACS journal Biomacromolecules.

8 Nov 2013

Array BioPharma reports net loss of $0.13 per share for first quarter of fiscal 2014

Array BioPharma Inc. today reported results for the first quarter of its fiscal year ending June 30, 2014.

31 Oct 2013

$Pivotal Study Supports Use of IMNOVID®▼ Pomalidomide in Patients with Relapsed or Refractory Multiple Myeloma$

Pivotal Study Supports Use of IMNOVID®▼ Pomalidomide in Patients with Relapsed or Refractory Multiple Myeloma

The Lancet Oncology published this week findings from a study, which showed that the new oral therapy IMNOVID®▼ (pomalidomide), used in combination with low-dose dexamethasone demonstrated a significant survival advantage over high-dose dexamethasone alone, in patients with relapsed and refractory multiple myeloma (rrMM).1

5 Sep 2013

Dexamethasone News and Research

Patrys reports positive results from PAT-SM6 clinical trial in patients with multiple myeloma

Pemetrexed plus erlotinib shows benefits in NSCLC

Elotuzumab granted Breakthrough Therapy Designation for treatment of multiple myeloma

Access provides update on new formulation of anti-inflammatory drug amlexanox

Heron initiates SUSTOL Phase 3 clinical trial for CINV prevention associated with emetogenic chemotherapy

Ocular Therapeutix starts Phase 3 clinical program to evaluate safety, efficacy of dexamethasone

Pharmacyclics total revenue for fourth quarter 2013 increases 113% to $123.6 million

New treatments for depression on the horizon

IMF announces approval of POMALYST medication in Canada for patients with myeloma

No added benefit from aflibercept, shows study

First patient enrolled in Otonomy's pivotal Phase 2b study of OTO-104 for Meniere's disease

Celgene subsidiary presents REVLIMID study results on lymphoma at ASH annual meeting

Celgene: FIRST trial meets primary endpoint in patients newly diagnosed with multiple myeloma

Takeda presents clinical study results of oral proteasome inhibitor MLN9708 in multiple myeloma patients

Acetylon Pharmaceuticals presents positive interim data from two ricolinostat clinical trials at ASH 2013

NOXXON Pharma reports interim data from two phase IIa studies of anti-CXCL12/SDF-1 Spiegelmer NOX-A12

Novartis to present updates on broad cancer portfolio at ASH and SABCS symposiums

Scientists to develop on-demand drug-delivery system for pain management in osteoarthritis patients

Array BioPharma reports net loss of $0.13 per share for first quarter of fiscal 2014

Pivotal Study Supports Use of IMNOVID®▼ Pomalidomide in Patients with Relapsed or Refractory Multiple Myeloma

Event guide: 4th Extra-Hepatic Lipid-Based Nanoparticles Delivery Summit eBook

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News